{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:26:27Z","timestamp":1782887187375,"version":"3.54.5"},"reference-count":123,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Spinal muscular atrophy (SMA) is an uncommon disorder associated with genes characterized by the gradual weakening and deterioration of muscles, often leading to substantial disability and premature mortality. Over the past decade, remarkable strides have been made in the field of SMA therapeutics, revolutionizing the landscape of patient care. One pivotal advancement is the development of gene-targeted therapies, such as nusinersen, onasemnogene abeparvovec and risdiplam which have demonstrated unprecedented efficacy in slowing disease progression. These therapies aim to address the root cause of SMA by targeting the survival motor neuron (SMN) gene, effectively restoring deficient SMN protein levels. The advent of these innovative approaches has transformed the prognosis for many SMA patients, offering a glimmer of hope where there was once limited therapeutic recourse. Furthermore, the emergence of small molecule compounds and RNA-targeting strategies has expanded the therapeutic arsenal against SMA. These novel interventions exhibit diverse mechanisms of action, including SMN protein stabilization and modulation of RNA splicing, showcasing the multifaceted nature of SMA treatment research. Collective efforts of pharmaceutical industries, research centers, and patient advocacy groups have played an important role in expediting the translation of scientific discoveries into visible clinical benefits. This review not only highlights the remarkable progress achieved in SMA therapeutics but also generates the ray of hope for the ongoing efforts required to enhance accessibility, optimize treatment strategies, rehabilitation (care and therapies) and ultimately pave the way for an improved quality of life for individuals affected by SMA.<\/jats:p>","DOI":"10.3389\/fneur.2024.1368658","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T05:17:50Z","timestamp":1716527870000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Diving into progress: a review on current therapeutic advancements in spinal muscular atrophy"],"prefix":"10.3389","volume":"15","author":[{"given":"Pankaj","family":"Bagga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gobind","family":"Ram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subham","family":"Kapil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avtar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.paed.2022.12.010","article-title":"Therapeutic advances in spinal muscular atrophy","volume":"33","author":"Willis","year":"2023","journal-title":"Paediatr Child Health"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1007\/s00415-023-11787-y","article-title":"Biomarkers in 5q-associated spinal muscular atrophy\u2014a narrative review","volume":"270","author":"Lapp","year":"2023","journal-title":"J Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1007\/s12325-023-02621-y","article-title":"Health care resource utilization and costs for patients with spinal muscular atrophy: findings from a retrospective US claims database analysis","volume":"40","author":"Toro","year":"2023","journal-title":"Adv Ther"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1038\/s41598-023-30449-7","article-title":"A comprehensive overview of SMN and NAIP copy numbers in Iranian SMA patients","volume":"13","author":"Savad","year":"2023","journal-title":"Sci Rep"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.1007\/s12325-023-02685-w","article-title":"Patient and caregiver outcomes after onasemnogene abeparvovec treatment: findings from the cure SMA 2021 membership survey","volume":"40","author":"Toro","year":"2023","journal-title":"Adv Ther"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s13023-023-02872-6","article-title":"Prevalence of morbidities across the lifespan for adults with spinal muscular atrophy: a retrospective cohort study","volume":"18","author":"Whitney","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3233\/JND-200610","article-title":"Burden of spinal muscular atrophy (SMA) on patients and caregivers in Canada","volume":"8","author":"McMillan","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1177\/0883073817716853","article-title":"The experience of families with children with spinal muscular atrophy type I across health care systems","volume":"32","author":"Murrell","year":"2017","journal-title":"J Child Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s10198-022-01548-5","article-title":"Significant healthcare burden and life cost of spinal muscular atrophy: real-world data","volume":"24","author":"Chan","year":"2023","journal-title":"Eur J Health Econ"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/BF01776636","article-title":"Zwei fr\u00fchinfantile heredit\u00e4re F\u00e4lle von progressiver Muskelatrophie unter dem Bilde der Dystrophie, aber anf neurotischer Grundlage","volume":"22","author":"Werdnig","year":"1891","journal-title":"Arch Psychiatr Nervenkr"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"151326","DOI":"10.1016\/j.ejcb.2023.151326","article-title":"Challenges and future perspective of antisense therapy for spinal muscular atrophy: a review","volume":"102","author":"Nakevska","year":"2023","journal-title":"Eur J Cell Biol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1007\/s13311-014-0293-y","article-title":"Spinal muscular atrophy: journeying from bench to bedside","volume":"11","author":"Awano","year":"2014","journal-title":"Neurotherapeutics"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1093\/brain\/87.4.707","article-title":"Infantile muscular atrophy a prospective study with particular reference to a slowly progressive variety","volume":"87","author":"Dubowitz","year":"1964","journal-title":"Brain"},{"key":"ref14","first-page":"395","article-title":"Hereditary proximal spinal muscular atrophy, a clinical entity simulating progressive muscular dystrophy","volume":"30","author":"Wohlfart","year":"1955","journal-title":"Acta Psychiatr Neurol Scand"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.braindev.2022.11.002","article-title":"Muscle impairment in MRI affect variability in treatment response to nusinersen in patients with spinal muscular atrophy type 2 and 3: a retrospective cohort study","volume":"45","author":"Shimizu-Motohashi","year":"2023","journal-title":"Brain Dev"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.neurol.2022.12.003","article-title":"Current treatments of spinal muscular atrophy in adults","volume":"179","author":"Cintas","year":"2023","journal-title":"Rev Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1007\/s00415-023-11560-1","article-title":"Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)","volume":"270","author":"Oskoui","year":"2023","journal-title":"J Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1007\/s40120-023-00552-y","article-title":"Evaluating perceived fatigue within an adult spinal muscular atrophy population","volume":"12","author":"Belter","year":"2023","journal-title":"Neurol Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/ene.14587","article-title":"Clinical and radiological profile of patients with spinal muscular atrophy type 4","volume":"28","author":"Souza","year":"2021","journal-title":"Eur J Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"11939","DOI":"10.3390\/ijms241511939","article-title":"Spinal muscular atrophy: the past, present, and future of diagnosis and treatment","volume":"24","author":"Nishio","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref21","first-page":"43","article-title":"Childhood spinal muscular atrophy","volume-title":"Handbook of clinical neurology","author":"Younger","year":"2023"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.4103\/1673-5374.339005","article-title":"NOVA1 promotes SMN2 exon 7 splicing by binding the UCAC motif and increases SMN protein expression","volume":"17","author":"Du","year":"2022","journal-title":"Neural Regen Res"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.neures.2023.04.007","article-title":"Dysregulation of Aldh1a2 underlies motor neuron degeneration in spinal muscular atrophy","volume":"194","author":"Kataoka","year":"2023","journal-title":"Neurosci Res"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"13743","DOI":"10.3390\/ijms241813743","article-title":"Emerging gene therapy approaches in the management of spinal muscular atrophy (SMA): an overview of clinical trials and patent landscape","volume":"24","author":"Ponomarev","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1002\/j.1460-2075.1996.tb00725.x","article-title":"A novel nuclear structure containing the survival of motor neurons protein","volume":"15","author":"Liu","year":"1996","journal-title":"EMBO J"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3390\/cells11030417","article-title":"Restoring SMN expression: an overview of the therapeutic developments for the treatment of spinal muscular atrophy","volume":"11","author":"Aslesh","year":"2022","journal-title":"Cells"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s41436-020-0754-0","article-title":"Spinal muscular atrophy diagnosis and carrier screening from genome sequencing data","volume":"22","author":"Chen","year":"2020","journal-title":"Genet Med"},{"key":"ref29","article-title":"Spinal muscular atrophy","volume-title":"GeneReviews","author":"Prior","year":"2020"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"120099","DOI":"10.1016\/j.jns.2021.120099","article-title":"Genetic architecture of motor neuron diseases","volume":"434","author":"Chaudhary","year":"2022","journal-title":"J Neurol Sci"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"146322","DOI":"10.1016\/j.gene.2022.146322","article-title":"Evaluation of exonic copy numbers of SMN1 and SMN2 genes in SMA","volume":"823","author":"Arikan","year":"2022","journal-title":"Gene"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/humu.24200","article-title":"Beyond copy number: a new, rapid, and versatile method for sequencing the entire SMN2 gene in SMA patients","volume":"42","author":"Blasco-P\u00e9rez","year":"2021","journal-title":"Hum Mutat"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.braindev.2013.11.009","article-title":"Intragenic mutations in SMN1 may contribute more significantly to clinical severity than SMN2 copy numbers in some spinal muscular atrophy (SMA) patients","volume":"36","author":"Yamamoto","year":"2014","journal-title":"Brain Dev"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.braindev.2017.03.002","article-title":"SMA mutations in SMN Tudor and C-terminal domains destabilize the protein","volume":"39","author":"Takarada","year":"2017","journal-title":"Brain Dev"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.ymthe.2020.01.013","article-title":"miR-206 reduces the severity of motor neuron degeneration in the facial nuclei of the brainstem in a mouse model of SMA","volume":"28","author":"Valsecchi","year":"2020","journal-title":"Mol Ther"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"7896","DOI":"10.3390\/ijms22157896","article-title":"Genomic variability in the survival motor neuron genes (SMN1 and SMN2): implications for spinal muscular atrophy phenotype and therapeutics development","volume":"22","author":"Butchbach","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41580-021-00382-6","article-title":"Molecular mechanisms underlying nucleotide repeat expansion disorders","volume":"22","author":"Malik","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"928581","DOI":"10.3389\/fmolb.2022.928581","article-title":"Structural context of a critical exon of spinal muscular atrophy gene","volume":"9","author":"Singh","year":"2022","journal-title":"Front Mol Biosci"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e524","DOI":"10.1212\/CPJ.0000000000000872","article-title":"Molecular biomarkers for spinal muscular atrophy: a systematic review","volume":"11","author":"Navarrete-Opazo","year":"2021","journal-title":"Neurol Clin Pract"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"8058","DOI":"10.3390\/ijms22158058","article-title":"The neuromuscular junction: roles in aging and neuromuscular disease","volume":"22","author":"Iyer","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41419-019-1727-6","article-title":"Reduced P53 levels ameliorate neuromuscular junction loss without affecting motor neuron pathology in a mouse model of spinal muscular atrophy","volume":"10","author":"Courtney","year":"2019","journal-title":"Cell Death Dis"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","article-title":"Spinal muscular atrophy","volume":"8","author":"Mercuri","year":"2022","journal-title":"Nat Rev Dis Prim"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1111\/jcmm.14939","article-title":"Nusinersen treatment and cerebrospinal fluid neurofilaments: an explorative study on spinal muscular atrophy type 3 patients","volume":"24","author":"Faravelli","year":"2020","journal-title":"J Cell Mol Med"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.nmd.2022.07.395","article-title":"Accuracy of muscle fasciculations for the diagnosis of later-onset spinal muscle atrophy","volume":"32","author":"MAR","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ncl.2020.03.002","article-title":"Spinal muscular atrophy in the treatment era","volume":"38","author":"Waldrop","year":"2020","journal-title":"Neurol Clin"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e248297","DOI":"10.1136\/bcr-2021-248297","article-title":"Late adult-onset spinal muscular atrophy with lower extremity predominance (SMALED)","volume":"15","author":"Aziz","year":"2022","journal-title":"BMJ Case Rep"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"e0230677","DOI":"10.1371\/journal.pone.0230677","article-title":"Diagnostic journey in spinal muscular atrophy: is it still an odyssey?","volume":"15","author":"Pera","year":"2020","journal-title":"PLoS One"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/acn3.51340","article-title":"Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment","volume":"8","author":"Freigang","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/jnnp-2021-326344","article-title":"Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis","volume":"92","author":"Shih","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.braindev.2020.09.005","article-title":"Clinical phenotypes of spinal muscular atrophy patients with hybrid SMN gene","volume":"43","author":"Niba","year":"2021","journal-title":"Brain Dev"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jmoldx.2021.03.004","article-title":"Multisite evaluation and validation of a sensitive diagnostic and screening system for spinal muscular atrophy that reports SMN1 and SMN2 copy number, along with disease modifier and gene duplication variants","volume":"23","author":"Milligan","year":"2021","journal-title":"J Mol Diagn"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s12035-023-03572-9","article-title":"Application of a multiplex ligation-dependent probe amplification-based next-generation sequencing approach for the detection of pathogenesis of Duchenne muscular dystrophy and spinal muscular atrophy caused by copy number aberrations","volume":"61","author":"Yang","year":"2023","journal-title":"Mol Neurobiol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.jmoldx.2020.03.001","article-title":"Carrier screening and prenatal diagnosis for spinal muscular atrophy in 13,069 Chinese pregnant women","volume":"22","author":"Zhang","year":"2020","journal-title":"J Mol Diagn"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s10897-015-9859-z","article-title":"Review of spinal muscular atrophy (SMA) for prenatal and pediatric genetic counselors","volume":"25","author":"Carr\u00e9","year":"2016","journal-title":"J Genet Couns"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.3390\/ijms21093297","article-title":"New and developing therapies in spinal muscular atrophy: from genotype to phenotype to treatment and where do we stand?","volume":"21","author":"Chen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s42466-021-00162-9","article-title":"Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders","volume":"4","author":"Jablonka","year":"2022","journal-title":"Neurol Res Pract"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"125173","DOI":"10.1016\/j.talanta.2023.125173","article-title":"Improvement of serum sample preparation and chromatographic analysis of nusinersen used for the treatment of spinal muscular atrophy","volume":"267","author":"Studzi\u0144ska","year":"2024","journal-title":"Talanta"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1186\/s12887-022-03671-x","article-title":"Advances and limitations for the treatment of spinal muscular atrophy","volume":"22","author":"Day","year":"2022","journal-title":"BMC Pediatr"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2478\/ahem-2022-0030","article-title":"Spinal muscular atrophy: where are we now? Current challenges and high hopes","volume":"76","author":"Przymusza\u0142a","year":"2022","journal-title":"Post\u0119py Hig Med Do\u015bw"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13023-023-02769-4","article-title":"Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience","volume":"18","author":"\u0141usakowska","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s13311-022-01200-3","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a systematic review and meta-analysis","volume":"19","author":"Gavriilaki","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","article-title":"Nusinersen: first global approval","volume":"77","author":"Hoy","year":"2017","journal-title":"Drugs"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.3389\/fphar.2020.592234","article-title":"Drug screening and drug repositioning as promising therapeutic approaches for spinal muscular atrophy treatment","volume":"11","author":"Menduti","year":"2020","journal-title":"Front Pharmacol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"8962","DOI":"10.3390\/ijms22168962","article-title":"Drug discovery of spinal muscular atrophy (SMA) from the computational perspective: a comprehensive review","volume":"22","author":"Chong","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","article-title":"Onasemnogene abeparvovec: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fneur.2020.00045","article-title":"The need for SMN-independent treatments of spinal muscular atrophy (SMA) to complement SMN-enhancing drugs","volume":"11","author":"Hensel","year":"2020","journal-title":"Front Neurol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/s41593-021-00827-3","article-title":"Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit","volume":"24","author":"van Alstyne","year":"2021","journal-title":"Nat Neurosci"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ppul.25055","article-title":"Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy","volume":"56","author":"Abreu","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/14656566.2019.1704732","article-title":"New treatments in spinal muscular atrophy: an overview of currently available data","volume":"21","author":"Ramdas","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"117485","DOI":"10.1016\/j.jns.2021.117485","article-title":"The potential role of miRNA therapies in spinal muscle atrophy","volume":"427","author":"Gandhi","year":"2021","journal-title":"J Neurol Sci"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.3390\/pharmaceutics15061764","article-title":"Expanding the availability of onasemnogene abeparvovec to older patients: the evolving treatment landscape for spinal muscular atrophy","volume":"15","author":"Ren\u00e9","year":"2023","journal-title":"Pharmaceutics"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s40265-020-01410-z","article-title":"Risdiplam: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/9781119847281.ch15","article-title":"Risdiplam (Evrysdi), a small molecule, SMN2-directed RNA splicing modifier for treating spinal muscular atrophy","volume-title":"Current drug synthesis","author":"Li","year":"2022"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40263-022-00910-8","article-title":"Risdiplam: a review in spinal muscular atrophy","volume":"36","author":"Paik","year":"2022","journal-title":"CNS Drugs"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/acn3.51560","article-title":"An expanded access program of risdiplam for patients with type 1 or 2 spinal muscular atrophy","volume":"9","author":"Kwon","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1080\/13543784.2022.2056836","article-title":"Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA)","volume":"31","author":"Markati","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3390\/brainsci11020194","article-title":"In search of a cure: the development of therapeutics to alter the progression of spinal muscular atrophy","volume":"11","author":"Ojala","year":"2021","journal-title":"Brain Sci"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.pediatrneurol.2020.01.003","article-title":"Overturning the paradigm of spinal muscular atrophy as just a motor neuron disease","volume":"109","author":"Yeo","year":"2020","journal-title":"Pediatr Neurol"},{"key":"ref80","first-page":"69","article-title":"Genetically targeted therapies for inherited neuromuscular disorders","author":"Brandsema","year":"2021","journal-title":"Pract Neurol"},{"key":"ref81","year":""},{"key":"ref82","year":""},{"key":"ref83","year":""},{"key":"ref84","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3233\/PRM-160360","article-title":"Physical therapy services received by individuals with spinal muscular atrophy (SMA)","volume":"9","author":"Dunaway","year":"2016","journal-title":"J Pediatr Rehabil Med"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.nmd.2021.02.011","article-title":"Filling the gaps in knowledge translation: physical therapy recommendations for individuals with spinal muscular atrophy compared to standard of care guidelines","volume":"31","author":"Trenkle","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"179","DOI":"10.31083\/j.fbl2706179","article-title":"Physical therapy and nusinersen impact on spinal muscular atrophy rehabilitative outcome","volume":"27","author":"Mirea","year":"2022","journal-title":"Front Biosci"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5734\/JGM.2020.17.2.55","article-title":"Rehabilitation of spinal muscular atrophy: current consensus and future direction","volume":"17","author":"Yi","year":"2020","journal-title":"J Genet Med"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1378\/chest.117.4.1100","article-title":"Spinal muscular atrophy type 1: a noninvasive respiratory management approach","volume":"117","author":"Bach","year":"2000","journal-title":"Chest"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"E55","DOI":"10.1002\/ppul.23693","article-title":"Noninvasive airway approaches for acute neuromuscular respiratory failure in emergency departments","volume":"52","author":"Chen","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"1753466619875928","DOI":"10.1177\/1753466619875928","article-title":"Combined noninvasive ventilation and mechanical insufflator-exsufflator for acute respiratory failure in patients with neuromuscular disease: effectiveness and outcome predictors","volume":"13","author":"Chen","year":"2019","journal-title":"Ther Adv Respir Dis"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2021.10296","article-title":"Effect of a sedation and ventilator liberation protocol vs usual care on duration of invasive mechanical ventilation in pediatric intensive care units: a randomized clinical trial","volume":"326","author":"Blackwood","year":"2021","journal-title":"JAMA"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11910-011-0240-9","article-title":"New therapeutic approaches to spinal muscular atrophy","volume":"12","author":"Lewelt","year":"2012","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.3390\/nu12123842","article-title":"Metabolic and nutritional issues associated with spinal muscular atrophy","volume":"12","author":"Li","year":"2020","journal-title":"Nutrients"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.nmd.2016.05.005","article-title":"Describing nutrition in spinal muscular atrophy: a systematic review","volume":"26","author":"Moore","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"109818","DOI":"10.1016\/j.ijporl.2019.109818","article-title":"Trajectory of change in the swallowing status in spinal muscular atrophy type I","volume":"130","author":"Choi","year":"2020","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.3390\/nu13072400","article-title":"Nutritional, gastrointestinal and endo-metabolic challenges in the management of children with spinal muscular atrophy type 1","volume":"13","author":"Corsello","year":"2021","journal-title":"Nutrients"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0887-8994(97)00227-0","article-title":"Treatment of type I spinal muscular atrophy with noninvasive ventilation and gastrostomy feeding","volume":"18","author":"Birnkrant","year":"1998","journal-title":"Pediatr Neurol"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.nmd.2020.12.007","article-title":"Feeding difficulties in children and adolescents with spinal muscular atrophy type 2","volume":"31","author":"Wadman","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13018-014-0144-x","article-title":"Determining the clinical importance of treatment benefits for interventions for painful orthopedic conditions","volume":"10","author":"Katz","year":"2015","journal-title":"J Orthop Surg Res"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/TACG.S53615","article-title":"Proximal spinal muscular atrophy: current orthopedic perspective","volume":"6","author":"Haaker","year":"2013","journal-title":"Appl Clin Genet"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15453\/2168-6408.1762","article-title":"Home use of an upper extremity exoskeleton in children with SMA: a pilot study","volume":"9","author":"Shank","year":"2021","journal-title":"Open J Occup Ther"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3109\/01942638.2010.493097","article-title":"Aquatic therapy for a child with type III spinal muscular atrophy: a case report","volume":"30","author":"Salem","year":"2010","journal-title":"Phys Occup Ther Pediatr"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"303","DOI":"10.5014\/ajot.55.3.303","article-title":"Factors affecting older adults\u2019 use of adaptive equipment: review of the literature","volume":"55","author":"Kraskowsky","year":"2001","journal-title":"Am J Occup Ther"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5195\/ijt.2018.6244","article-title":"Feasibility and effectiveness of telehealth occupational therapy home modification interventions","volume":"10","author":"Renda","year":"2018","journal-title":"Int J Telerehabil"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/1440-1630.12564","article-title":"Novice occupational therapists: navigating complex practice contexts in South Africa","volume":"66","author":"van Stormbroek","year":"2019","journal-title":"Aust Occup Ther J"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"7S45","DOI":"10.1016\/S0929-693X(20)30277-3","article-title":"Multidisciplinary approach and psychosocial management of spinal muscular atrophy (SMA)","volume":"27","author":"Ropars","year":"2020","journal-title":"Arch Pediatr"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"5360","DOI":"10.3390\/ijerph20075360","article-title":"Experiences of health care and psychosocial needs in parents of children with spinal muscular atrophy","volume":"20","author":"Inhestern","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/HRP.0b013e318283bf8f","article-title":"Interventions for children affected by war: an ecological perspective on psychosocial support and mental health care","volume":"21","author":"Betancourt","year":"2013","journal-title":"Harv Rev Psychiatry"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fped.2020.00004","article-title":"Palliative care in SMA type 1: a prospective multicenter French study based on parents\u2019 reports","volume":"8","author":"Hully","year":"2020","journal-title":"Front Pediatr"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1212\/CPJ.0000000000000718","article-title":"A multidisciplinary approach to dosing nusinersen for spinal muscular atrophy","volume":"9","author":"Zingariello","year":"2019","journal-title":"Neurol Clin Pract"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/disabilities1010001","article-title":"Enhancing function, fun and participation with assistive devices, adaptive positioning, and augmented mobility for young children with infantile-onset spinal muscular atrophy: a scoping review and illustrative case report","volume":"1","author":"Livingstone","year":"2021","journal-title":"Disabilities"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3109\/17483107.2010.525292","article-title":"Use of orthoses and orthopaedic technical devices in proximal spinal muscular atrophy. Results of survey in 194 SMA patients","volume":"6","author":"Fujak","year":"2011","journal-title":"Disabil Rehabil Assist Technol"},{"key":"ref114","doi-asserted-by":"crossref","DOI":"10.1101\/2022.03.21.484406","article-title":"Exon7 targeted CRISPR-prime editing approaches for SMN2 gene editing in spinal muscular atrophy (SMA) disease can increase in vitro SMN expression","author":"Odabas","year":"2022"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1002\/humu.24120","article-title":"SMN1 copy-number and sequence variant analysis from next-generation sequencing data","volume":"41","author":"Lopez-Lopez","year":"2020","journal-title":"Hum Mutat"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"10067","DOI":"10.1021\/acs.jmedchem.6b00670","article-title":"Small molecules in development for the treatment of spinal muscular atrophy: miniperspective","volume":"59","author":"Calder","year":"2016","journal-title":"J Med Chem"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2147\/TCRM.S172291","article-title":"Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives","volume":"15","author":"Dangouloff","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/mus.27034","article-title":"Combination molecular therapies for type 1 spinal muscular atrophy","volume":"62","author":"Harada","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/jnc.14974","article-title":"Combinatorial treatment for spinal muscular atrophy: an editorial for \u2018combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in spinal muscular atrophy cells\u2019 on page 264","volume":"153","author":"Poletti","year":"2020","journal-title":"J Neurochem"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/jcsm.12542","article-title":"Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy","volume":"11","author":"Zhou","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"147","DOI":"10.5694\/mja17.00772","article-title":"Screening for spinal muscular atrophy","volume":"209","author":"Sampaio","year":"2018","journal-title":"Med J Aust"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/jnnp-2017-317412","article-title":"Nusinersen for SMA: expanded access programme","volume":"89","author":"Farrar","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40273-021-01105-7","article-title":"Systematic literature review to assess the cost and resource use associated with spinal muscular atrophy management","volume":"40","author":"Paracha","year":"2022","journal-title":"PharmacoEconomics"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1368658\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T05:17:55Z","timestamp":1716527875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1368658\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":123,"alternative-id":["10.3389\/fneur.2024.1368658"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1368658","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,24]]},"article-number":"1368658"}}